BioIVT, a provider of biospecimens and related services, has acquired Ascendance Biotechnology, Inc. Ascendance was formed as a multinational cell-based assay company in November 2015 through the merger of Hepregen Corporation and the ESI BIO products division of BioTime Inc. As a result of the acquisition, BioIVT has added Hepregen’s HepatoPac, HepatoMune and HepatoStem liver cell and stem cell product lines to its drug safety testing and toxicology portfolios.
Hepregen’s products employ a patented cell micropatterning technology in which different cell types are plated on industry-standard micro-well plates in proprietary patterns. The plates provide in-vitro cellular co-cultures that have a longer life and improved function. The HepatoPac products feature primary hepatocytes and fibroblasts that have been micro-patterned to create hepatocyte islands surrounded by supportive stromal cells. This approach closely mimics the function of a human liver and allows the hepatocytes to maintain normal metabolic activity for several weeks.
With HepatoMune, the micro-patterned primary hepatocytes and fibroblasts are supplemented with primary Kupffer cells, creating highly functional human liver tissue that models inflammation-mediated hepatotoxicity. HepatoMune tri-cultures remain viable for at least ten days, retaining both liver cell and Kupffer cell functionality, and can be used for predicting clinical outcomes. HepatoStem applies the same micro-patterning technology to stem cells.
For further information about BioIVT visit www.bioivt.com
Latest from Tom Mulligan
- EVENT PREVIEW: CPhI North America opens next week!
- NEW BUSINESS: SK biotek and AMPAC Fine Chemicals have ambitious CDMO plans
- NEW TECHNOLOGY: Polyplus-transfection develops GMP-grade therapeutic virus reagent
- Mogrify raises $3.7 million seed funding to support direct cellular conversion for cell therapy
- Owlstone Medical partners with Shanghai Renji Hospital to pioneer Breath Biopsy lung cancer trial
- Chemspace and LabNetwork collaborate to extend access to chemical databases
- TECHNOLOGY UPDATE: Catalent invests over $27 million to commercialise next-generation ODT Zydis Ultra
- SGS reports successful Phase 2 results for novel influenza vaccine, validating its H3N2 A/Belgium challenge agent
- NEW TECHNOLOGY: Horizon Discovery and Rutgers University develop new gene editing approach: ‘base editing’
- EVENT REVIEW: Busy sessions at BIO-Europe Spring!